Albemarle (NYSE:ALB – Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that wish to listen to the company’s earnings conference call can do so using this link.
Albemarle Stock Up 2.4 %
ALB stock opened at $100.57 on Tuesday. The company has a market capitalization of $11.82 billion, a P/E ratio of -21.26 and a beta of 1.55. Albemarle has a 12 month low of $71.97 and a 12 month high of $153.54. The firm’s fifty day simple moving average is $92.35 and its 200-day simple moving average is $100.75. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.75.
Albemarle Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Friday, December 13th will be given a dividend of $0.405 per share. This represents a $1.62 annualized dividend and a yield of 1.61%. The ex-dividend date is Friday, December 13th. Albemarle’s dividend payout ratio is currently -34.25%.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on ALB
Albemarle Company Profile
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.
Featured Stories
- Five stocks we like better than Albemarle
- Canada Bond Market Holiday: How to Invest and Trade
- Intel: Is Now the Time to Be Brave?Â
- 3 Warren Buffett Stocks to Buy Now
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Invest in the FAANG Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.